{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.0","value":"865"},{"groupId":"OG001","spread":"100","value":"1006"},{"groupId":"OG002","spread":"50.0","value":"1432"},{"groupId":"OG003","spread":"67.4","value":"743"},{"groupId":"OG004","spread":"144","value":"1111"},{"groupId":"OG005","spread":"74.0","value":"1627"},{"groupId":"OG006","spread":"33.1","value":"1567"},{"groupId":"OG007","spread":"79.5","value":"589"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"3"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"title":"Cycle 1 Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"83.5","value":"836"},{"groupId":"OG001","spread":"111","value":"2802"},{"groupId":"OG002","spread":"38.4","value":"2382"},{"groupId":"OG003","spread":"80.4","value":"1624"},{"groupId":"OG004","spread":"109","value":"1805"},{"groupId":"OG005","spread":"104","value":"2562"},{"groupId":"OG006","spread":"104","value":"2511"},{"groupId":"OG007","spread":"59","value":"1402"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"5"},{"groupId":"OG002","value":"5"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"6"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"2"},{"groupId":"OG007","value":"9"}],"units":"Participants"}],"title":"Cycle 1 Day 21"}],"denoms":[{"counts":[{"groupId":"OG000","value":"6"},{"groupId":"OG001","value":"6"},{"groupId":"OG002","value":"6"},{"groupId":"OG003","value":"6"},{"groupId":"OG004","value":"7"},{"groupId":"OG005","value":"8"},{"groupId":"OG006","value":"5"},{"groupId":"OG007","value":"12"}],"units":"Participants"}],"description":"Plasma samples for determination of Cobimetinib concentration were collected prior to dosing and at 2, 4, 6 and 24 hours after dosing on Days 1 and 21 of Cycle 1. The sampling will allow determination of AUC0-24.","dispersionType":"Geometric Coefficient of Variation","groups":[{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG000","title":"Phase I (Tablet) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG001","title":"Phase I (Tablet) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG002","title":"Phase I (Tablet) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.6 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG003","title":"Phase I (Suspension) Cobimetinib (0.6 mg/kg)"},{"description":"Dose-Escalation: Participants received 0.8 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG004","title":"Phase I (Suspension) Cobimetinib (0.8 mg/kg)"},{"description":"Dose-Escalation: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG005","title":"Phase I (Suspension) Cobimetinib (1 mg/kg)"},{"description":"Dose-Escalation: Participants received 1.33 milligrams per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG006","title":"Phase I (Suspension) Cobimetinib (1.33 mg/kg)"},{"description":"Dose-Expansion: Participants received 1 milligram per kilogram (mg/kg) cobimetinib orally once daily on Days 1 to 21 of each 28-day treatment cycle.","id":"OG007","title":"Phase II (Suspension) Cobimetinib (1 mg/kg)"}],"paramType":"GEOMETRIC_MEAN","populationDescription":"The PK population was defined as all participants who received at least 1 dose of Cobimetinib and had evaluable PK data. Only participants for whom data were collected are included in the analysis.","reportingStatus":"POSTED","timeFrame":"Pre-dose, 2, 4, 6, and 24 hours post-dose on Cycle 1 Days 1 and 21 (pre-dose=within 4 hours prior to dose; cycle length=28 days)","title":"Area Under the Concentration-Time Curve From 0 to 24 Hours (AUC0-24) of Cobimetinib","type":"SECONDARY","unitOfMeasure":"hr*ng/mL"}